RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Amneal Pharmaceuticals Stock

Amneal Pharmaceuticals P/E 2024

Amneal Pharmaceuticals P/E

6.38

Ticker

AMRX

ISIN

US03168L1052

WKN

A2JLMD

As of Jul 16, 2024, Amneal Pharmaceuticals's P/E ratio was 6.38, a -221.29% change from the -5.26 P/E ratio recorded in the previous year.

The Amneal Pharmaceuticals P/E history

Amneal Pharmaceuticals Aktienanalyse

What does Amneal Pharmaceuticals do?

Amneal Pharmaceuticals Inc is a leading pharmaceutical company headquartered in Bridgewater, New Jersey, USA. It was founded in 2002 by Chirag Patel and Chintu Patel, both of whom were involved in the generic pharmaceutical industry. Amneal specializes in the development, manufacturing, and marketing of high-quality, cost-effective generic and specialty pharmaceuticals for a variety of therapeutic areas. The company's mission is to help patients worldwide by producing and delivering high-quality, cost-effective medications. Amneal operates globally in over 50 countries, with global facilities in India, Ireland, and other countries. The company strives to provide innovation, exceptional service, and reliability to customers and patients worldwide. Over the years, the company has rapidly grown to become a major player in the global pharmaceutical market. It offers a wide range of products, including both generic and specialty pharmaceuticals in numerous therapy areas. These areas include oncology, central nervous system (CNS), gastroenterology, dermatology, immunology, pain management, and many others. Amneal places a strong emphasis on clinical research and development to create innovative medications and therapies that meet the needs of today's patients. The company has multiple research and development centers worldwide, including in Israel, India, and the USA, where it collaborates closely with industry partners to develop new products. Another hallmark of Amneal is its ability to provide high-quality generic pharmaceuticals that meet the needs of customers in different countries and regions. The company manufactures its products to the highest standards and has a strict quality assurance system to ensure that patients can rely on receiving medications of the highest quality and efficacy. Amneal's product line is extensive, encompassing a variety of drugs ranging from simple over-the-counter (OTC) preparations to complex steroids and oncology therapeutics. Some of its key products include Tamoxifen Citrate, Lamotrigine, Methylphenidate Hydrochloride, Warfarin Sodium, Buprenorphine-Naloxone, and many others. Amneal Pharmaceuticals also forms partnerships with other companies to expand and diversify its business model. In 2018, Amneal merged with Impax Laboratories, Inc., a leading pharmaceutical company specializing in the development, manufacturing, and marketing of generic and specialty products for various therapy areas. The merger brought together both companies, creating an entity with a broader product portfolio, a larger global reach, and stronger development and marketing expertise. In summary, Amneal Pharmaceuticals Inc is a leading pharmaceutical company focused on the development and marketing of generic and specialty pharmaceuticals for a variety of therapeutic areas. The company is on a mission to help patients worldwide by producing and delivering high-quality, cost-effective medications. Amneal prioritizes clinical research and development to create innovative medications and therapies, and it has a strict quality assurance system. The company has a wide product range and collaborates closely with other companies to expand its business model and global reach. Amneal Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Amneal Pharmaceuticals's P/E Ratio

The Price to Earnings (P/E) Ratio of Amneal Pharmaceuticals is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Amneal Pharmaceuticals's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Amneal Pharmaceuticals is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Amneal Pharmaceuticals’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Amneal Pharmaceuticals stock

What is the price-to-earnings ratio of Amneal Pharmaceuticals?

The price-earnings ratio of Amneal Pharmaceuticals is currently 6.38.

How has the price-earnings ratio of Amneal Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Amneal Pharmaceuticals has increased by -221.29% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Amneal Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Amneal Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Amneal Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Amneal Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Amneal Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Amneal Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Amneal Pharmaceuticals?

Some factors that influence the price-earnings ratio of Amneal Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Amneal Pharmaceuticals pay?

Over the past 12 months, Amneal Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amneal Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Amneal Pharmaceuticals?

The current dividend yield of Amneal Pharmaceuticals is .

When does Amneal Pharmaceuticals pay dividends?

Amneal Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Amneal Pharmaceuticals?

Amneal Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Amneal Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Amneal Pharmaceuticals located?

Amneal Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amneal Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amneal Pharmaceuticals from 7/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.

When did Amneal Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/16/2024.

What was the dividend of Amneal Pharmaceuticals in the year 2023?

In the year 2023, Amneal Pharmaceuticals distributed 0 USD as dividends.

In which currency does Amneal Pharmaceuticals pay out the dividend?

The dividends of Amneal Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Amneal Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Amneal Pharmaceuticals

Our stock analysis for Amneal Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amneal Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.